|
|
|
|
|||||
|
|
|
Exelixis, Inc. (NASDAQ:EXEL) is one of the 13 Best Low Risk High Growth Stocks to Buy.
The company advances its studies following a significant rise in price targets from analysts.
Based in California, Exelixis, Inc. (NASDAQ:EXEL) is a biotechnology company focused on discovering, developing, and commercializing oncology medicines. It is known for its work in oncology, specifically with small-molecule therapies and antibody-drug conjugates. The company’s key products include CABOMETYX (cabozantinib) and COMETRIQ. With these products, the company targets difficult-to-treat cancers such as renal cell and medullary thyroid carcinoma.
On June 10, 2025, Barclays, while keeping an Equal Weight rating on the stock, raised its price target from $29 to $40. Reflecting the sentiment, UBS also raised its price target on the stock from $38 to $43, while maintaining a Neutral rating.
With the new price targets indicating confidence in the company’s progress, Exelixis, Inc. (NASDAQ:EXEL) provided updates on its ongoing clinical studies. Study of XL092 has entered Phase 3, where its efficiency with nivolumab is tested in comparison to sunitinib in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) who have not received prior systemic anticancer therapy. The company also announced a Phase 1 clinical study on XL309 to estimate its safety and preliminary efficacy, both alone and in combination with olaparib, in treating advanced solid tumors.
In addition to these advances in cancer treatment, investors are also intrigued by the company’s low volatility, represented by the beta of 0.30 and the potential EPS growth of 32.12% in the next five years.
While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025
Disclosure. None.
| Jul-24 | |
| Jul-23 | |
| Jul-23 | |
| Jul-23 | |
| Jul-23 | |
| Jul-22 | |
| Jul-21 | |
| Jul-21 | |
| Jul-21 | |
| Jul-20 | |
| Jul-19 | |
| Jul-17 | |
| Jul-15 | |
| Jul-15 | |
| Jul-15 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite